| Literature DB >> 34048833 |
Yuxi Guo1, Xuefeng Chen2, Pin Gong3.
Abstract
The deficiency of chemical-synthesized antiviral drugs when applied in clinical therapy, such as drug resistance, and the lack of effective antiviral drugs to treat some newly emerging virus infections, such as COVID-19, promote the demand of novelty and safety anti-virus drug candidate from natural functional ingredient. Numerous studies have shown that some polysaccharides sourcing from edible and medicinal fungus (EMFs) exert direct or indirect anti-viral capacities. However, the internal connection of fungus type, polysaccharides structural characteristics, action mechanism was still unclear. Herein, our review focus on the two aspects, on the one hand, we discussed the type of anti-viral EMFs and the structural characteristics of polysaccharides to clarify the structure-activity relationship, on the other hand, the directly or indirectly antiviral mechanism of EMFs polysaccharides, including virus function suppression, immune-modulatory activity, anti-inflammatory activity, regulation of population balance of gut microbiota have been concluded to provide a comprehensive theory basis for better clinical utilization of EMFs polysaccharides as anti-viral agents.Entities:
Keywords: Antiviral activity; Edible and medicinal fungus; Polysaccharides
Mesh:
Substances:
Year: 2021 PMID: 34048833 PMCID: PMC8144117 DOI: 10.1016/j.ijbiomac.2021.05.139
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 8.025
Fig. 1Statistical analysis of the literature on the antiviral activity of edible and medicinal fungus polysaccharides. (a) Antiviral polysaccharides derived from EMFs related papers published between 2000– 2020 (based on Web of Science). (b) Antiviral EMFs polysaccharides effect related biological activity papers. (c) The categories of antiviral EMFs polysaccharides. (d) Antiviral EMFs polysaccharides investigate the relationship among immunomodulatory activity, anti-inflammatory activity, improve gut function, and antiviral activity.
Abbreviations: BHV (BoHV)-1: Bovine herpesvirus 1; BIDV (IBDV)-1: Infections bursal disease virus 1; EV 71: Human enterovirus 71; FCV: Feline calicivirus; H1N1: Influenza A virus; HBV: Viral hepatitis type B; HIV: Human immunodeficiency virus; HPV: Human papillomavirus; HSV: Herpes simplex virus; MDRV: Muscovy duck reovirus; NDV: Newcastle disease virus; PV-1: Poliovirus 1).
The composition of monosaccharides, molecular weight, antiviral activity, and cytotoxicity of polysaccharides from the edible mushroom.
| Classification | Polysaccharides name | Monosaccharide composition | MW (kDa) | Structural feature | Biological activity | Ref. |
|---|---|---|---|---|---|---|
| MCP | Only Man | 81.2 | →6)-α-D-Man | Immunomodulatory activity | [ | |
| MIPW50-1 | GlcNAc:Gal:Glc:Man = 1.00:14.95:1.53:10.51 | 28.5 | →2,3,6)-α-D-Man | Immunomodulatory activity | [ | |
| CMP-III | Glc:Man:Gal = 8.09:1.00:0.25 | 47,960 | 1 → 4)-α-D-Glc | Immunomodulatory activity | [ | |
| SDQCP-1 | Man:Glc:Gal = 13.3:1.0:9.7 | 19.3 | Backbone composed of (1 → 2)-α-D-Man | Immunomodulatory activity | [ | |
| UM01 PS | Glc:Man:Gal = 100:59:17 | 610,86,25 | (1 → 6)-α-D-glucosidic linkages | Immunomodulatory activity | [ | |
| HS002-II | Man:Rib:Rha:GlcAc:GalAc:Glu:Gal:Xyl:Ara = 6.47:2. | 44 | Backbone composed of (1 → 3)-α-D-Rib (1 → 4)-α-D-Xyl and (1 → 4)-β-D-Glc, which was substituted at C-6. | Immunomodulatory activity | [ | |
| SB2-1 | Glc:Gal:Man = 2.0:1.5:1.0 | 22.2 | The Man core was composed of (1 → 2)-Man | Immunomodulatory activity | [ | |
| WCCP-N-b | Gal:3-O-Me-D-Gal:Glc:Man = 14.4:4.6:1.0:1.2 | 18 | A linear methylated galactan which was composed of α-(1 → 6)-α-D-Gal | Immunomodulatory activity | [ | |
| CC-1 | Glc:Xyl = 5:1 | 61,056 | Backbone composed of (1 → 4)-β-D-Glc | Immunomodulatory activity | [ | |
| CCP | Man:Gal:Glc:Xyl = 48.73:17.37:15.97:17.93 | 1970 | (1 → 3)-β-D-Man | Immunomodulatory activity | [ | |
| PSG-1 | Man:Gal:Glc = 1:1.28:4.91 | 1013 | The main glycosidic linkage types composed of→3)-Glc | Immunomodulatory activity | [ | |
| GSG | ND | 8 | GSG is a branched glucan that contains (1 → 3)-linked, (1 → 3,6)-linked, (1 → 6)-linked and (1 → 4) linked | Immunomodulatory activity | [ | |
| GSP-2 | Only Glc | 32 | Backbone composed of (1 → 4)-and (1 → 6)-β-D-Glc | Immunomodulatory activity | [ | |
| HEP-S | Rha:Fuc:Man:Glc:Gal = 1.47:0.93:1.36:8.68:4.08 | 18.3 | The main glycosidic linkage types composed of (1→)-α-D-Glc, (1 → 3,4)-α-D-Glc, (1 → 6)-α-D-Gal, (1 → 3,4)-β-D-Man, (1 → 3,6)-α-Rha and (1 → 2)-β-L-Fuc | Immunomodulatory activity | [ | |
| HEP-W | Rha:Fuc:Man:Glc:Gal = 0.98:1.59:0.89:5.60:7.06 | 15.9 | The main glycosidic linkage types consisted of (1→)-α-D-Glc, (1 → 3,6)-α-D-Glc, (1 → 2,6)-α-D-Gal, T-β-Gal, (1 → 3,4)-β-D-Man, (1 → 3)-α-Rha, and (1 → 2)-β-L-Fuc | Immunomodulatory activity | [ | |
| DBFM3 | Man:GlcAc:Gal = 1:18.16:0.702 | 180 | (1 → 6), (1 → 3,6), (1 → 3) linkages and pyranose conformation | Immunomodulatory activity | [ | |
| PRA-1 | 2,3,4,6-Me4-Glc:2,4,6-Me3-Glc:2,4-Me2-Glc = 5.72:1.00:2.41 | 24,190;109.6;4.12 | Hyperbranched (1 → 3), (1 → 6)-β-D-glucan with a degree of branching of 0.89, backbone composed of →1)-D-Glc | Immunomodulatory activity | [ | |
| G1 | Ara:Fru:Gal:Glc = 1.6:3.8:19.7:19.7 | 151 | Furanoid rings; β-glycosidic bonds between the sugar units | Anti-HIV activity | [ | |
| GF-P | Fuc:Gal:Glc:Man:Rib:GlcAc = 5.8:10.5:72.2:7.8:2.2:1.2 | 19.6;722.7 | Contained the highest amount of (1 → 3,6)-β-D-glucans. | Immunomodulatory activity | [ | |
| GFP1 | Glc:Fuc = 2.3:0.5 | 40.5 | (1 → 6)-β-D-Glc | Anti-EV 71 activity | [ | |
| IOI-WN | Ara:Rha:Fuc:Xyl:Man:Gal:Glc:GlcAc:GalAc:3- | 60 | (1) The neutral polysaccharides were heterogeneous and branched and consisted of a (1 → 3)-linked β-Glc backbone with (1 → 6)-linked kinks in the chain at approximately every fifth residue, with branches of (1 → 6)-linked β-Glc in addition to substantial amounts of (1 → 6)-linked α-Gal with 3- | Immunomodulatory activity | [ | |
| IOI-WAC | Ara:Rha:Fuc:Xyl:Man:Gal:Glc:GlcAc:GalAc:3- | 15 | ||||
| Rha:Man:Ara:Gal:Xyl:Glc = 1.31:14.51:2.63:20.65:3.32:57.58 | 18.518 | The glycosidic linkages were mostly 1 → 3, 1 → 6 or 1 → 3,6. main chain of →3)-β-D-Glc | Immunomodulatory activity | [ | ||
| PPE | Man:Gal:Glc = 38.40:1.00:1.76 | 38 | Backbone of (1 → 2)-linked Man, which was heavily substituted | Immunomodulatory activity | [ | |
| ZPS | >90% Glc | 227 | (1 → 6, 1 → 4)-linked β-D-Glc | Immunomodulatory activity | [ | |
| HBP | Only Glc | 430 | Backbone of (1 → 6)-β-D-Glc | Immunomodulatory activity | [ | |
| CEPSN-1 | Glc:Man:Gal:GlcAc = 98.90:0.11:0.38:0.61 | 4.6 | Backbone chain composed of (1 → 4)-α-D-Glc | Immunomodulatory activity | [ | |
| CEPSN-2 | Glc:Man:Gal:Ara:Fuc:GluAc:GalAc = 97.56:0.14:1.04:0.11:0.45:0.50:0.20 | 6.7 | ||||
| TP | Man:Xyl:GlcAc = 57.50:32.09:10.14 | 1500 | Backbone was composed of (1 → 3)-β-D-Man | Immunomodulatory activity | [ | |
| TAP-3 | Man:Xyl:GlcAc = 3.0:1.0: 1.0. | 624 | Backbone was composed of (1 → 3) and (1 → 2)-α-Man | Immunomodulatory activity | [ | |
| DIP | Man:Rib:Rha:GlcAc:Glc:Gal:Xyl:Ara:Fuc = 23.55:0.46:0.043:1.014:59.84:12.95:0.36:0.17:1.58 | 650 | β-(1 → 3)-D-Glc with side branches of β-(1 → 6)-Glc units | Immunomodulatory activity | [ | |
| ABS | Glc:Man:Gal:Gal-Me:Fuc:Ribe = 51.4:6.8:33.9:3.0:1.6:3.3 | ND | (1 → 6), (1 → 4)-α-Glc, (1 → 6)-β-Glc, and mannogalactan | Anti-inflammatory activity | [ | |
| FR-S | ND | 3.5 | (1 → 6)-(1 → 3)-β-D-glucan | Anti-HSV activity | [ | |
| AAPS | Rha:Fuc:Man:Glc = 2.90:10.25:3.70:38.27 | 18.1 | α-LRha | Immunomodulatory activity | [ | |
| BSF-X | Glc:Gal = 2:1 | 141.309 | Backbone of 1, 4-β-D-Glc of which branches were mainly composed of two 1, 6-α-D-Gal residue and a 4-β-D-Glc at the end of the branches | Immunomodulatory activity | [ | |
| BEP | Glc:Gal:Rha:Ara = 2.9:3.2:1.3:1.6 | 113.432 | Backbone consisting of (1 → 6)-linked-α-D-Glc | Immunomodulatory activity | [ | |
| LRP-1 | Gal:Rha:Fuc:Man:Glc:Gala = 25.77:1.98:4.99:27.45:39.13:0.68 | 18.82 | Backbone mainly composed of →1-α-D-Fuc | Immunomodulatory activity | [ | |
| RPS | ND | 3.08 | →3)-L-Rha | Anti-inflammatory activity | [ | |
| ERPS | ND | 1.16 | →3)-L-Rha | |||
| LA | Glc:Rha:GlcA:Xyl:Gal = 26.3:2.7:1.0:1.4:1.8:1.2 | 120 | [→6)-α-D-Glc | Anti-HIV activity | [ | |
| PCPS | 1, 5, 6-Tri- | 450 | Backbone mainly composed of β-(1 → 6)-Glcp withβ-(1 → 6)-Glcp residues branched | Immunomodulatory activity | [ | |
| WPEP-N-b | Gal:Man:3-O-Me-D-Gal:Glc = 43.8:39.3: 11.7:9.20 | 21.4 | Backbone mainly composed of α-(1 → 6)-D-Gal | Immunomodulatory activity | [ | |
| EPA-1 | Man:Glc:Gal = 2.20:1.00:3.20 | 99.7 | Backbone mainly composed of (1 → 6)-Gal residue | Immunomodulatory activity | [ | |
| PfloVv5FB | 1,5-Di- | 187 | Repeating unit of the polysaccharide has a backbone of three (1 → 6)-linked β-D-Glc | Immunomodulatory activity | [ | |
| Heteropolysaccharide | Glc:Gal = 7:1 | 187 | Backbone mainly composed of →3)-β-D-Glc | Immunomodulatory activity | [ | |
| β-Glucan | Xyl:Man:Gal:Glc = 2:5:3:90 | ND | (1 → 3)β-D-Glc | Anti-inflammatory activity | [ | |
| PEIsR | Man:Gal:3-Omethyl-Gal =37.0:39.7:23.3 | 64 | Main chain of (1 → 6)-α-D-Gal | Anti-inflammatory activity | [ | |
| VGPI-a | Only Glc | 1435.6 | (1 → 4)-D-Glc | Immunomodulatory activity | [ | |
| AMPS-1-1 | Glc:Gal:GlcA = 89.06:9.59:1.34 | 123 | (1→)-β-D-Glc | Immunomodulatory activity | [ | |
| AMPS-2-1 | Glc:Gal:GlcA:Man = 65.28:22.87:2.87:8.98 | 676 | (1 → 3,6)-α-D-Glc | |||
| FVP2 | Gal:Glc:Man = 19.96:60.66:19.38 | 18.3 | (1 → 3)-β-D-Gal, (1 → 6)-β-D-Gal, (1 → 6)-α-D-Glc and (1 → 3,6)-α-D-Man | Improves gut microbiota function | [ | |
| FVPB2 | Gal:Man:Fuc:Glc = 1.9:1.2:1:2.5 | 15 | Backbone mainly composed of →2)-α-D-Gal | Immunomodulatory activity | [ | |
| PS | Glc:Gal:Man = 3:1:1 | 200 | Backbone mainly composed of →6)-β-D-Glc | Immunomodulatory activity | [ | |
Abbreviations: glucose (Glc), xylose (Xyl), rhamnose (Rha), mannose (Man), fucose (Fuc), fructose (Fru), galactose (Gal), arabinose (Ara), ribose (Rib), glucuronic acid (GlcA), and galacturonic acid (GalA).
Due to table typesetting, the classification of “subphyla, class, order” in the table and Table S2 is presented in the form of “no indentation”, “family” is indented by 1 character, “genus and species” is indented by 2 characters.
Fig. 2Common EMFs with direct or indirect antiviral effects.
Fig. 3Structures of common EMFs polysaccharides with direct or indirect antiviral effects. (a) Proposed structure of MIPW50–1 (Morchella importuna polysaccharide); (b) Putative structure of HBP (Sarcodon aspratus (Berk.) polysaccharide); (c) NOESY and HMBC correlations of TAP-3 (Tremella aurantialba Bandoni et Zang glucuronoxylomannan); (d) The structure of polysaccharide BSF-X (Boletus speciosus Frost polysaccharide); (e) Proposed structure of the polysaccharides from the fruiting bodies of G. sinense; (f) The proposed main structure of the galactoglucomannan SB1–1 (Shiraia bambusicola polysaccharide); (g) One possible structure of Pleurotus eryngii polysaccharide (EPA-1) (m = 5, n = 2).
Fig. 4Review on Antiviral mechanisms of EMFs polysaccharides.